Showing results (381-390 of 3,351) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|November 1, 2019
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trialYeon Hee Park, Tae-Yong Kim, Gun Min Kim, et al.
The Lancet. Oncology|November 1, 2019
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trialAlice T Shaw, Benjamin J Solomon, Rita Chiari, et al.
The Lancet. Oncology|January 14, 2020
Automated deep-learning system for Gleason grading of prostate cancer using biopsies: a diagnostic studyWouter Bulten, Hans Pinckaers, Hester van Boven, et al.
The Lancet. Oncology|February 6, 2019
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trialCharles S Fuchs, Kohei Shitara, Maria Di Bartolomeo, et al.
The Lancet. Oncology|January 15, 2019
Short-term safety outcomes of mastectomy and immediate implant-based breast reconstruction with and without mesh (iBRA): a multicentre, prospective cohort studyShelley Potter, Elizabeth J Conroy, Ramsey I Cutress, et al.
The Lancet. Oncology|February 13, 2019
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trialJohann S de Bono, Nicole Concin, David S Hong, et al.
The Lancet. Oncology|January 20, 2019
Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trialDavid Cella, Viktor Grünwald, Bernard Escudier, et al.
The Lancet. Oncology|December 4, 2018
Consensus on molecular imaging and theranostics in prostate cancerStefano Fanti, Silvia Minozzi, Gerald Antoch, et al.
The Lancet. Oncology|December 4, 2018
Defining priority medical devices for cancer management: a WHO initiativeAdriana Velazquez Berumen, Gabriela Jimenez Moyao, Natalia M Rodriguez, et al.
The Lancet. Oncology|January 19, 2020
Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trialMichael R Migden, Nikhil I Khushalani, Anne Lynn S Chang, et al.
Pageof 336